Tiziania is developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.
IL-6r mAb has a novel mechanism of action, binding to both the membrane-bound and soluble forms of the IL-6r, blocking the IL-6/IL-6r complex as well as depleting circulating levels of IL-6 in the blood.
Excessive production of IL-6 is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma, oncology indications, severe acute respiratory distress syndrome (ARDS), lupus, autoimmune inflammatory diseases and rheumatoid arthritis. We believe that TZLS-501 may have the potential therapeutic value to fight these indications.
In preclinical studies, TZLS-501 demonstrated that its novel mechanism of action has the potential to overcome the limitations of other IL-6 blocking pathway drugs.
Tiziana’s anti-IL-6R mAb binds to both the membrane-bound and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in blood. Excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness. China’s National Health Commission has recommended the use of anti-IL6-R mAbs for treatment of inflammation and elevated cytokine levels (“cytokine storm”) in COVID-19 patients. A recent study also reported that COVID-19 infection caused clusters of severe respiratory illness like ARDS.
Tiziana Life Sciences; Novimmune
Planned Time to Trials
6 - 12 Months
Hover for more information.
No items found.
Get In Touch
Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.